P56100
吡嗪酸
99%
别名:
吡嗪-2-羧酸
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C5H4N2O2
化学文摘社编号:
分子量:
124.10
UNSPSC Code:
12352100
NACRES:
NA.22
PubChem Substance ID:
EC Number:
202-718-1
Beilstein/REAXYS Number:
112305
MDL number:
Assay:
99%
Form:
powder
InChI
1S/C5H4N2O2/c8-5(9)4-3-6-1-2-7-4/h1-3H,(H,8,9)
InChI key
NIPZZXUFJPQHNH-UHFFFAOYSA-N
SMILES string
OC(=O)c1cnccn1
assay
99%
form
powder
mp
222-225 °C (dec.) (lit.)
Quality Level
正在寻找类似产品? 访问 产品对比指南
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Wanliang Shi et al.
Science (New York, N.Y.), 333(6049), 1630-1632 (2011-08-13)
Pyrazinamide (PZA) is a first-line tuberculosis drug that plays a unique role in shortening the duration of tuberculosis chemotherapy. PZA is hydrolyzed intracellularly to pyrazinoic acid (POA) by pyrazinamidase (PZase, encoded by pncA), an enzyme frequently lost in PZA-resistant strains
Anthony D Baughn et al.
Antimicrobial agents and chemotherapy, 54(12), 5323-5328 (2010-09-30)
The pyrazinamide (PZA) analog 5-chloropyrazinamide (5-Cl PZA) is active against mycobacterial species, including PZA-resistant strains of Mycobacterium tuberculosis. In M. smegmatis, overexpression of the type 1 fatty acid synthase (FAS I) confers resistance to 5-Cl PZA, a potent FAS I
Michael Groll et al.
Structure (London, England : 1993), 14(3), 451-456 (2006-03-15)
The dipeptide boronic acid bortezomib, also termed VELCADE, is a proteasome inhibitor now in use for the treatment of multiple myeloma, and its use for the treatment of other malignancies is being explored. We determined the crystal structure of the
João P S Fernandes et al.
Archiv der Pharmazie, 343(2), 91-97 (2010-01-26)
Tuberculosis is an infection caused mainly by Mycobacterium tuberculosis. A first-line antimycobacterial drug is pyrazinamide (PZA), which acts partially as a prodrug activated by a pyrazinamidase releasing the active agent, pyrazinoic acid (POA). As pyrazinoic acid presents some difficulty to
Takashi Iwanaga et al.
The Journal of pharmacology and experimental therapeutics, 320(1), 211-217 (2006-10-18)
Serum uric acid (SUA) is currently recognized as a risk factor for cardiovascular disease. It has been reported that an angiotensin II receptor blocker (ARB), losartan, decreases SUA level, whereas other ARBs, such as candesartan, have no lowering effect. Because
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持